ClinicalTrials.gg
Active, not recruitingNCT04961996Updated Oct 15, 2026

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

A Phase 3 interventional study of Giredestrant and Physician's Choice of Endocrine Therapy in Early Breast Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 621 sites in 54 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 15, 20266 sites added7 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing giredestrant in Breast Neoplasms — 4 open to participants now, 12 under way, 7 of them phase 3. giredestrant · Breast Neoplasms.

Enrollment
Largest of 16
4,170 · median 302
Started
2021
the only one that year
Phase 3
7 of 16
2 open now
Primary completion
2025-08
later than 2 of 11 live
Registered
6th of 16
by date
Lead sponsor
8 of 16
Hoffmann-La Roche

Among the 16 studies testing giredestrant in Breast Neoplasms, this one has the largest enrollment, is the only one that started in 2021, is one of 7 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies testing giredestrant in Breast Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About giredestrant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing giredestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

03

Conditions studied

  • Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented estrogen receptor (ER)-positive and -negative breast tumor, as assessed locally on a primary disease specimen
  • Participants who have multicentric (the presence of two of more tumor foci within different quadrants of the same breast) and/or multifocal (the presence of two or more tumor foci within a single quadrant of the breast) breast cancer are also eligible if all examined tumors meet pathologic criteria for ER positivity and HER2 negativity
  • Participants must have undergone definitive surgery of their primary breast tumor(s) and axillary lymph nodes (axillary lymph node dissection [ALND] and/or sentinel lymph node [SLNB])
  • Participants who received or will be receiving chemotherapy must have completed adjuvant chemotherapy prior to randomization. Participants may also have received neoadjuvant chemotherapy. A of at least 21 days is required between last adjuvant chemotherapy dose and randomization.
  • Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to v5.0 Grade 1 or better (except alopecia, Grade ≤2 peripheral neuropathy, arthralgia or other toxicities not considered a safety risk for the participant per the investigator's judgment)
  • Participants have received (neo)adjuvant chemotherapy and/or had surgery and had no prior endocrine therapy are eligible, provided that they are enrolled within 12 months following definitive breast cancer surgery
  • Participants who have confirmed availability of an untreated primary breast tumor tissue specimen suitable for biomarker testing (i.e., representative archived formalin-fixed, paraffin-embedded [FFPE] tissue block [preferred] or 15-20 slides containing unstained, freshly cut, serial sections), with associated de-identified pathology report is required. Although 15-20 slides are preferred, if only 10-14 slides are available, the individual may still be eligible for the study.
  • Participants with node-positive and node-negative disease are eligible provided they meet additional risk criteria as defined in the protocol
  • (ECOG) Performance Status 0, 1, or 2
  • Able and willing to swallow, retain, and absorb oral medication
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 10 days after the final dose of giredestrant, or within the time period specified per local prescribing guidelines after the final dose of the endocrine therapy of physician's choice
  • Received treatment with therapy within 28 days prior to initiation of study treatment or is currently enrolled in any other type of medical research judged by the sponsor not to be scientifically or medically compatible with this study
  • Receiving or planning to receive a CDK4/6 inhibitor as (neo) therapy. A short course of up to 12 weeks of neoadjuvant or adjuvant treatment with CDK4/6 inhibitor therapy prior to randomization is allowed.
  • Active cardiac disease or history of cardiac dysfunction
  • Diagnosed with Stage IV breast cancer
  • A history of any prior (ipsilateral and/or contralateral) invasive breast cancer or ductal carcinoma in situ (DCIS). Participants with a history of contralateral DCIS treated by only local regional therapy at any time may be eligible.
  • A history of any other within 3 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, or Stage I uterine cancer
  • Any prior endocrine treatment with selective ER modulators (e.g., tamoxifen), degraders, or aromatase inhibitors. A short course of neoadjuvant or adjuvant endocrine therapy (up to 12 weeks) is allowed.
  • liver disease consistent with Class B or C, including active hepatitis (e.g., virus [HBV] or virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis
  • Treatment with strong inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment
  • Known allergy or to any of the study drugs or any of their
  • Pre- and perimenopausal participants or male participants who have a known hypersensitivity to LHRH agonists
  • A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism
  • Renal dysfunction that requires dialysis
  • A major surgical procedure unrelated to breast cancer within 28 days prior to randomization
  • A serious infection requiring oral or IV antibiotics within 14 days prior to screening or other clinically significant infection (e.g., COVID-19) within 14 days prior to screening
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
  • Unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,170 participants (actual)

Study arms

  • Experimental
    Arm A: Giredestrant

    Drug: Giredestrant · Drug: LHRH Agonist

  • Active comparator
    Arm B: Physician's Choice of Endocrine Therapy

    Drug: Physician's Choice of Endocrine Therapy · Drug: LHRH Agonist

Interventions

  • Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).

    Also known as: GDC-9545, RO7197597, RG6171

  • DrugPhysician's Choice of Endocrine Therapy

    The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive PCET daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing PCET after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of PCET should be performed in accordance with the local prescribing information for the respective product.

  • A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. LHRH agonists may include, but are not limited to, leuprolide acetate, goserelin acetate, or triptorelin pamoate. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

This study also gives Anastrozole, Exemestane. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast Cancers

    Time frame: From randomization to first occurrence of an IDFS event (up to 10 years)

Secondary outcomes

  1. Overall Survival

    Time frame: From randomization to death from any cause (up to 10 years)

  2. Invasive Disease-Free Survival (IDFS), Including Second Primary Non-Breast Cancers

    Time frame: From randomization to first occurrence of an IDFS event (up to 10 years)

  3. Disease-Free Survival (DFS)

    Time frame: From randomization to first occurrence of a DFS event (up to 10 years)

  4. Distant Recurrence-Free Interval (DRFI)

    Time frame: From randomization to first occurrence of a DFRI event (up to 10 years)

  5. Locoregional Recurrence-Free Interval (LRRFI)

    Time frame: From randomization to first occurrence of a LRRFI event (up to 10 years)

  6. Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  7. Change from Baseline in the Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  8. Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  9. Change from Baseline in the Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  10. Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  11. Change from Baseline in the Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  12. Change from Baseline in the EQ 5D-5L Index-Based Score at Specified Timepoints

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  13. Change from Baseline in the EQ 5D-5L Visual Analogue Scale (VAS) Score at Specified Timepoints

    Time frame: Baseline (Cycle 1) and Cycles 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 (1 cycle is 28 days) of treatment, once every 6 months during the first 2 years of post-treatment follow-up and annually for 3 years thereafter (up to 10 years)

  14. Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)

    Time frame: From start of treatment until 28 days after the final dose of study treatment (up to 5 years)

  15. Plasma Concentrations of Giredestrant at Specified Timepoints

    Time frame: Predose and 3-4 hours postdose on Day 1 of Cycles 1 and 2, and predose on Day 1 of Cycles 3 and 6 (1 cycle is 28 days)

07

Study locations

621 sites

Showing the first 100 of 621 sites across 54 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Aug 2025, 47 months.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 47 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Jul 14, 2021
StartActual
Aug 27, 2021
Primary completionActual
Aug 8, 2025
CompletionEst.
Sep 30, 2033
Results delay requested
Jun 8, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added, 7 sites removed
Show 6 added (2 United States, 1 Egypt, 1 Japan, 1 Portugal, 1 South Korea)
  • Cancer and Blood Specialty Clinic-California-Katella Ave · Los Alamitos, United States
  • Texas Oncology (Grandview) - USOR · El Paso, United States
  • Mansoura University Hospital · Markaz El Mansoura, Egypt
  • Saitama Prefectural Cancer Center · Shinden, Japan
  • Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E · Vila Nova de Gaia, Portugal
  • Inha University Hospital · Jemulpo-gu, South Korea
Show 7 removed
  • Cancer Blood and Specialty Clinic · Los Alamitos, United States
  • Texas Oncology, P.A. - El Paso · El Paso, United States
  • Mansoura University Hospital · Al Mansurah, Egypt
  • Saitama Cancer Center · Kitaadachi-gun, Japan
  • Oncologia S.A.C. - Instituto Peruano de Oncología & Radioterapia · Lima, Peru
  • Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E · Vila Nova de Gaia, Portugal
  • Inha University Hospital · Incheon, South Korea
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    6 sites added, 7 sites removed
    Show 6 added (2 United States, 1 Egypt, 1 Japan, 1 Portugal, 1 South Korea)
    • Cancer and Blood Specialty Clinic-California-Katella Ave · Los Alamitos, United States
    • Texas Oncology (Grandview) - USOR · El Paso, United States
    • Mansoura University Hospital · Markaz El Mansoura, Egypt
    • Saitama Prefectural Cancer Center · Shinden, Japan
    • Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E · Vila Nova de Gaia, Portugal
    • Inha University Hospital · Jemulpo-gu, South Korea
    Show 7 removed
    • Cancer Blood and Specialty Clinic · Los Alamitos, United States
    • Texas Oncology, P.A. - El Paso · El Paso, United States
    • Mansoura University Hospital · Al Mansurah, Egypt
    • Saitama Cancer Center · Kitaadachi-gun, Japan
    • Oncologia S.A.C. - Instituto Peruano de Oncología & Radioterapia · Lima, Peru
    • Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E · Vila Nova de Gaia, Portugal
    • Inha University Hospital · Incheon, South Korea
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04961996
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 14, 2021
Start date
Aug 27, 2021
Primary completion
Aug 8, 2025
Completion
Sep 30, 2033 (estimated)
Last update
Oct 15, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Giredestrant

Start the discussion